作者
Xiaodong Wang,Xiaohui Yang,Chang Zhang,Yang Wang,Tianyou Cheng,Liqiang Duan,Zhou Tong,Shuguang Tan,Hangjie Zhang,Phei Er Saw,Yinmin Gu,Jinhua Wang,Yibi Zhang,Lina Shang,Yajuan Liu,Siyuan Jiang,Bingxue Yan,Rong Li,Yue Yang,Jie Yu,Yunzhao Chen,George F. Gao,Qinong Ye,Shan Gao
摘要
Significance This study indicates that a subpopulation of tumor cells expresses both PD-1 and PD-L1, which decreases the tumor growth by suppressing the canonical signaling pathways, i.e. the AKT and ERK1/2 pathways. In the absence of adaptive immune system, tumor cell-intrinsic PD-1/PD-L1 mediates the resistance to the treatment with FDA-approved anti-PD-1/PD-L1 antibodies by activating AKT and ERK1/2. These findings provide an additional explanation for resistance to cancer immunotherapy.